Health
Clinical trial testing efficacy of antibody against SARS-CoV-2 begins – Medical Xpress
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
For the BLAZE-1 trial, UChicago is recruiting 22 participants to be treated with the LY-CoV555 antibody developed by Eli Lilly and Company in collaboration with AbCellera. The antibody was first identified by scientists at the National Institute of Allergy and Infectious Diseases and AbCe…
-
General22 hours agoa pivotal moment in Liberal power struggle
-
Noosa News22 hours agoTayla Harris stars as Melbourne defeats Essendon by 14 points
-
General20 hours agoRussia launches its biggest attack on Ukraine’s gas network since war began on the eve of winter
-
General12 hours agoWork to do: net-zero jobs yet to resonate in classroom